KCM
SCPH

Kennedy Capital Management’s scPharmaceuticals SCPH Stock Holding History

Kennedy Capital Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-218,812
Closed -$952K – 728
2024
Q2 		$952K Sell
218,812
-942
-0.4% -$4.14K 0.02% 594
2024
Q1 		$1.1M Sell
219,754
-3,246
-1% -$18.2K 0.02% 614
2023
Q4 		$1.4M Sell
223,000
-3,604
-2% -$20.6K 0.03% 547
2023
Q3 		$1.61M Hold
226,604
– – 0.04% 496
2023
Q2 		$2.31M Hold
226,604
– – 0.05% 432
2023
Q1 		$2.06M Hold
226,604
– – 0.06% 397
2022
Q4 		$1.62M Buy
+226,604
New +$1.38M 0.05% 436

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Kennedy Capital Management's SCPH Position: Q3 2024 in Review

Kennedy Capital Management sold out of scPharmaceuticals (SCPH) in Q3 2024, closing a stake of 218,812 shares — an estimated $952K sold.

Kennedy Capital Management first reported a position in SCPH in Q4 2022 and held it in 7 quarters. The position peaked at $2.31M in Q2 2023. 95 funds tracked by Wall St. Rank hold SCPH as of Q3 2024.

  • Kennedy Capital Management reported no remaining scPharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 218,812 scPharmaceuticals shares in Q3 2024, an estimated $952K.
  • Kennedy Capital Management first reported a position in scPharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Kennedy Capital Management's scPharmaceuticals position peaked at $2.31M in Q2 2023.
  • 95 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2024.

Based on Kennedy Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.